

# 1 Title

2 C-reactive protein guided use of procalcitonin in COVID-19

## 3 Authors

4 Rebecca Houghton<sup>1</sup>, Nathan Moore<sup>1</sup>, Rebecca Williams<sup>1</sup>, Fatima El-Bakri<sup>1</sup>, Jonathan Peters<sup>1</sup>, Matilde Mori<sup>1</sup>,  
5 Gabrielle Vernet<sup>1</sup>, Jessica Lynch<sup>1</sup>, Henry Lewis<sup>1</sup>, Maryanna Tavener<sup>1</sup>, Tom Durham<sup>1</sup>, Jack Bowyer<sup>1</sup>, Kordo  
6 Saeed<sup>2,3</sup>, Gabriele Pollara<sup>4,5</sup>

7 <sup>1</sup>Hampshire Hospitals NHS Foundation Trust, UK

8 <sup>2</sup>University Hospital Southampton NHS Foundation Trust, UK

9 <sup>3</sup>University of Southampton, School of Medicine, Southampton, UK

10 <sup>4</sup>Royal Free London NHS Foundation Trust, UK

11 <sup>5</sup>University College London, UK

## 12 Corresponding author

13 Dr Gabriele Pollara, Division of Infection & Immunity, University College London, London, WC1E 6BT, UK.

14 Email: [g.pollara@ucl.ac.uk](mailto:g.pollara@ucl.ac.uk)

15

## 16 Short title

17 CRP guided use of PCT in COVID-19

## 18 Keywords

19 COVID-19; procalcitonin; C-reactive protein; antimicrobial stewardship;

## 20 Abstract

21 Low procalcitonin (PCT) concentrations (<0.5ng/mL) can facilitate exclusion of bacterial co-infection in viral  
22 infections, including COVID-19. However, costs associated with PCT measurement preclude universal  
23 adoption, indicating a need to identify settings where PCT provides clinical information beyond that offered  
24 by other inflammatory markers, such as C-reactive protein (CRP) and white cell count (WCC). In an unselected  
25 cohort of 299 COVID-19 patients, we tested the hypothesis that PCT<0.5ng/mL was associated with lower  
26 levels of CRP and WCC. We demonstrated that CRP values below the geometric mean of the entire patient  
27 population had a negative predictive value for PCT<0.5ng/mL of 97.6% and 100% at baseline and 48 hours  
28 into admission respectively, and that this relationship was not confounded by intensive care admission or  
29 microbiological findings. CRP-guided PCT testing algorithms can reduce costs and support antimicrobial  
30 stewardship strategies in COVID-19.

## Main text

Unnecessary antibiotic prescriptions during the COVID-19 pandemic will increase selection for antibiotic resistance (1). Optimising antimicrobial stewardship approaches in COVID-19 is a global priority, and a recent study has indicated that procalcitonin (PCT)  $<0.5\text{ng/mL}$  offered a high negative predictive value ( $>95\%$ ) for the presence of bacterial co-infections (2). Elevated PCT is associated more frequently with bacterial than viral infections (3), and thus low PCT can support cessation of antibiotic prescriptions in both COVID-19 and non-COVID-19 settings (4–8). Unlike the inflammatory markers C-reactive protein (CRP) and white cell count (WCC), PCT is not routinely measured (9), partly due to the costs associated with its testing (10,11). Elevations in PCT, CRP and WCC can be concordant (12), and therefore a key research question is to identify scenarios in which PCT provides clinical information beyond that offered by other inflammatory markers, in turn informing algorithms that avoid the expense of redundant PCT measurements.

We identified 299 adult patients with compatible clinical syndromes for COVID-19 and SARS-CoV-2 confirmed on molecular testing, admitted to Hampshire Hospitals NHS Trust between 5<sup>th</sup> March and 26<sup>th</sup> April 2020. The measurement of PCT, CRP and WCC at baseline and daily during hospital admission was standard of care. We tested the hypothesis that PCT concentration was closely related to CRP or WCC levels, choosing  $\text{PCT} \geq 0.5\text{ng/mL}$  as threshold for the presence of bacterial pulmonary infection (4,7,8,13,14).  $\text{PCT} \geq 0.5\text{ng/mL}$  was associated with greater levels of CRP on admission and 48 hours into admission, independent of the need for intensive care unit (ICU) admission during the hospital stay (figs 1A+C). In contrast,  $\text{PCT} \geq 0.5\text{ng/mL}$  was associated with only a modestly greater WCC in non-ICU attending patients (fig 1B+D). Next, we used pairwise comparison to test the hypothesis that low levels of CRP/WCC could exclude  $\text{PCT} \geq 0.5\text{ ng/mL}$ . We used the geometric mean of CRP or WCC for the entire patient population at each timepoint as cut-offs for low and high levels of these markers. Strikingly, low CRP was strongly associated with  $\text{PCT} < 0.5\text{ng/mL}$  (NPV 97.6% and 100% at baseline and 48 hours into admission respectively) (fig 1C). A similar relationship was observed for WCC, although with lower NPV (91.0% and 84.9% respectively) (fig 1D). Notably, patients with significant microbiological results, as previously defined (2), were not associated with elevated levels of any inflammatory marker (fig 1C+D) (9).

We demonstrate low CRP concentrations can predict low PCT values in COVID-19, precluding the cost of this test in approximately a third of patients. We acknowledge the retrospective, single-centre nature of the study, and the unspecified interval between symptom onset and hospital admission. However, these limitations are countered by the large, unselected populations, the consistent relationship between variables at both time points, and the independence from ICU admission status. The lack of association between PCT and microbiology results was notable and reminiscent of observations made in COVID-19 for other inflammatory markers (9). The diagnostic stewardship role for PCT in excluding bacterial co-infection at high CRP levels will need investigating through studies comparing COVID-19 with syndromically-defined bacterial pneumonia (9,15).

We declare no conflicts of interest.

## 68 Figure legend

69 **Figure 1:** Association between CRP or WCC and the concentration of PCT in COVID-19. Concentration of CRP  
70 (A) or enumeration of WCC (B) stratified by PCT concentration  $<0.5$  or  $\geq 0.5$  ng/mL and by requirement for ICU  
71 admission during hospital stay. Assessments were made on admission to hospital (“baseline”) and 48 hours  
72 into hospital admission (“48h”). All p values derived using 2-tailed Mann-Whitney tests. Relationship  
73 between PCT and CRP concentration (C) or WCC (D). Scatter plot horizontal line represent PCT concentration  
74 cut-off ( $\geq 0.5$  ng/mL) and vertical line represents geometric mean of all patients at each timepoint,  
75 independent of PCT concentration. Total number of patients in each quadrant of scatter plot quantified in  
76 table below. Red dots and bracketed numbers reflect number of patients with significant microbiological  
77 findings. Sensitivity, specificity, PPV and NPV given for CRP (E) or WCC (F) to identify high or low PCT  
78 concentrations.

## References

1. Nieuwlaat R, Mbuagbaw L, Mertz D, Burrows L, Bowdish DME, Moja L, et al. COVID-19 and Antimicrobial Resistance: Parallel and Interacting Health Emergencies. Clin Infect Dis. 2020 Jun 16;
2. May M, Chang M, Dietz D, Shoucri S, Laracy J, Sobieszczyk ME, et al. Limited Utility of Procalcitonin in Identifying Community-Associated Bacterial Infections in Patients Presenting with Coronavirus Disease 2019. Antimicrob Agents Chemother. 2021 Jan 25;
3. Self WH, Balk RA, Grijalva CG, Williams DJ, Zhu Y, Anderson EJ, et al. Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia. Clin Infect Dis. 2017 Jul 15;65(2):183–190.
4. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016 Jul;16(7):819–827.
5. Williams EJ, Mair L, de Silva TI, Green DJ, House P, Cawthron K, et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study. J Hosp Infect. 2021 Jan 20;
6. Peters C, Williams K, Un EA, Little L, Saad A, Lendrum K, et al. Use of procalcitonin for antibiotic stewardship in patients with COVID-19: A quality improvement project in a district general hospital. Clin Med. 2020 Dec 18;
7. Heesom L, Rehnberg L, Nasim-Mohi M, Jackson AIR, Celinski M, Dushianthan A, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. J Glob Antimicrob Resist. 2020 Jul 25;22:782–784.
8. Drewett GP, Smibert OC, Holmes NE, Trubiano JA. The Use of Procalcitonin as an Antimicrobial Stewardship Tool and a Predictor of Disease Severity in COVID-19. Infect Control Hosp Epidemiol. 2021 Jan 25;1–5.

9. Mason CY, Kanitkar T, Richardson CJ, Lanzman M, Stone Z, Mahungu T, et al. Exclusion of bacterial co-infection in COVID-19 using baseline inflammatory markers and their response to antibiotics. J Antimicrob Chemother. 2021 Jan 19;
10. Kip MMA, Kusters R, IJzerman MJ, Steuten LMG. A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ. 2015 Jul 20;18(11):944–953.
11. Lubell Y, Do NTT, Nguyen KV, Ta NTD, Tran NTH, Than HM, et al. C-reactive protein point of care testing in the management of acute respiratory infections in the Vietnamese primary healthcare setting - a cost benefit analysis. Antimicrob Resist Infect Control. 2018 Oct 4;7:119.
12. Saeed K, Dale AP, Leung E, Cusack T, Mohamed F, Lockyer G, et al. Procalcitonin levels predict infectious complications and response to treatment in patients undergoing cytoreductive surgery for peritoneal malignancy. Eur J Surg Oncol. 2016 Feb;42(2):234–243.
13. Schuetz P, Beishuizen A, Broyles M, Ferrer R, Gavazzi G, Gluck EH, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019 Aug 27;57(9):1308–1318.
14. Vaughn VM, Gandhi T, Petty LA, Patel PK, Prescott HC, Malani AN, et al. Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study. Clin Infect Dis. 2020 Aug 21;
15. Karaba SM, Jones G, Helsel T, Smith LL, Avery R, Dzintars K, et al. Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study. Open Forum Infect Dis. 2021 Jan;8(1):ofaa578.

## Figure 1

